A combination of IGSF11 inhibition with anti-PD-1 or anti-CTLA-4 treatments can augment the activation of T-cell populations, activate the exhausted T-cell pools, and enhance the repertoire of immunity toward the tumor antigens. The gene discussed is PDCD1; the disease is neoplasm.